EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

GLP ‐1 Receptor Agonist–Based Prandial Insulin De‐Intensification in Outpatients With Type 2 Diabetes Receiving Basal–Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials

Hongxia Yang, Tianli Ren, Jin Zhou, Hao Liu, Fen Yin, Zhengtang Liu iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11407-11417

DOI: 10.1111/dom.71359 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 14.09.2026. Verfasst von Hongxia Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Insulin. Die Arbeit nennt 40 Literaturangaben. Gefördert von: CACMS Innovation Fund, National key research and development program, Beijing research ward construction program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This systematic review and meta‐analysis aimed to compare GLP‐1 receptor agonist (GLP‐1RA)‐based prandial insulin de‐intensification with continued basal–bolus insulin therapy (BBI) or multiple daily injections (MDI) in adult outpatients with type 2 diabetes receiving established BBI/MDI at randomisation. Materials and Methods PubMed, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL) and Web of Science were searched for randomised controlled trials enrolling adult outpatients with type 2 diabetes receiving established BBI/MDI at randomisation. Eligible trials compared a GLP‐1RA‐based strategy involving protocol‐directed withdrawal, replacement or substantial reduction of scheduled prandial insulin while maintaining basal insulin versus continued BBI/MDI therapy. The primary outcome was change in HbA1c. Secondary outcomes included changes in body weight, total daily insulin dose (TDD), hypoglycaemia and de‐intensification‐related outcomes.

Results

Seven randomised controlled trials involving 1332 participants were included. Compared with continued BBI/MDI therapy, GLP‐1RA‐based prandial insulin de‐intensification was not associated with a significant difference in HbA1c change (mean difference [MD] −0.08 percentage points, 95% confidence interval [CI] −0.28 to 0.12; p = 0.391). The de‐intensification strategy was associated with reductions in body weight (MD −4.94 kg, 95% CI −7.37 to −2.51; p = 0.003) and total daily insulin dose (MD −33.32 U/day, 95% CI −52.23 to −14.41; p = 0.006). The risk of experiencing at least one hypoglycaemic event was lower with GLP‐1RA‐based de‐intensification (risk ratio [RR] 0.76, 95% CI 0.66 to 0.87; p = 0.007).

Conclusions

In adults with type 2 diabetes receiving established BBI/MDI therapy, GLP‐1RA‐based prandial insulin de‐intensification was associated with maintenance of short‐term glycaemic control while reducing body weight and total daily insulin requirements. A potential reduction in hypoglycaemia remains uncertain. This strategy may represent an option for treatment optimisation in appropriately selected patients receiving intensive insulin therapy; however, further studies are needed to determine its long‐term sustainability and optimal implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinHumansRandomized Controlled Trials as TopicGlycated HemoglobinDrug Administration ScheduleBlood GlucoseOutpatientsGlycemic ControlHypoglycemia

Stichwörter der Autor:innen

GLP‐1 receptor agonistbasal–bolus insulinde‐intensificationmeta‐analysisprandial insulintype 2 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinGlycated HemoglobinBlood Glucosehemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Geriatrics, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
  • Graduate School of Beijing University of Chinese Medicine, Beijing, China.

ORCID-Profile: Zhengtang Liu

Förderung

  • CACMS Innovation Fund
  • National key research and development program
  • Beijing research ward construction program
  • High level key discipline program
  • National Key Research and Development Program of China

Zitieren

APA

Yang, H., Ren, T., Zhou, J., Liu, H., Yin, F., & Liu, Z. (2026). GLP ‐1 Receptor Agonist–Based Prandial Insulin De‐Intensification in Outpatients With Type 2 Diabetes Receiving Basal–Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism, 28(12), 11407-11417. https://doi.org/10.1111/dom.71359

Vancouver

Yang H, Ren T, Zhou J, Liu H, Yin F, Liu Z. GLP ‐1 Receptor Agonist–Based Prandial Insulin De‐Intensification in Outpatients With Type 2 Diabetes Receiving Basal–Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026;28(12):11407-11417. doi:10.1111/dom.71359

BibTeX
@article{Yang2026,
  author = {Yang, Hongxia and Ren, Tianli and Zhou, Jin and Liu, Hao and Yin, Fen and Liu, Zhengtang},
  title = {GLP ‐1 Receptor Agonist–Based Prandial Insulin De‐Intensification in Outpatients With Type 2 Diabetes Receiving Basal–Bolus Insulin Therapy or Multiple Daily Injections: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11407--11417},
  doi = {10.1111/dom.71359}
}
Kostenlos starten →